Abstract
Polypharmacy in managing severe tuberculosis patients usually poses a risk of adverse drug reactions. Contezolid is a new oxazolidinone antibiotic showing good in vitro and in vivo activity against Mycobacterium tuberculosis. Contezolid add-on regimen shows promising efficacy and safety results in managing severe tuberculosis patients complicated with acute thrombocytopenia.